Search

Boehringer Ingelheim annouces 2020 BVDzero Case Awards

Boehringer Ingelheim is announcing the 2020 ‘BVDzero Case Awards’ are now open for applications. The bi-annual awards reflect the long-term commitment to promoting the health and well-being of farm animals.

Advancing green chemistry for more sustainable medicines

By applying the principles of eco-design and green chemistry, we developed an innovative manufacturing process with reduced environmental footprint.

Boehringer Ingelheim reaches more patients than ever, innovation drives growth

Boehringer Ingelheim reports a strong performance in 2022.

Veterinary oncology experts meet in Germany

Veterinary oncology experts meet prior to the European Society of Veterinary Oncology Congress in Hofheim, Germany

biopharmaceuticals-in-china

Boehringer Ingelheim manufactures the first biopharmaceutical approved in China under new MAH contract manufacturing regulatory system.

Listen to the sounds disrupting farms worldwide

A pioneer in Precision Livestock Farming, Prof. Daniel Berckmans reveals how online monitoring technology is bringing healthier pigs closer to farmers and consumers

New positive data in Phase III type 2 diabetes trial

DINAMO Phase III trial demonstrated empagliflozin significantly reduced blood sugar levels in children and adolescents with type 2 diabetes

European_Commission_approves_nintedanibSSc-ILD

Nintedanib is approved as the first and only treatment of systemic sclerosis-associated interstitial lung disease

Refolding of Inclusion Bodies

Two new claims for Nexgard range in EU and Australia

Boehringer Ingelheim expands the label claims of its NexGard® brands for the treatment of two severe skin diseases in dogs in the EU and in Australia.

meat consumption market trends growth sustainability

In this article, we’re taking a look at global developments while highlighting one of the most important meat markets of the future: the Asian continent.

Innovation and drone delivery

Addressing healthcare disparities through collaborative innovation and drone delivery

PRRS vaccine celebrates 25 years in Europe

Boehringer Ingelheim celebrates 25 years to combat PRRS in Europe

Reduction of Salmonella in swine after vaccination

Authorities acknowledge reduction of Salmonella after vaccination with Enterisol® Ileitis

EMA authorization for Reprocyc ParvoFLEX

Boehringer Ingelheim obtains EMA authorization for Reprocyc® ParvoFLEX, a new porcine parvovirus vaccine

Launch of Frontline flagship store on Tmall

Boehringer Ingelheim launches Frontline flagship store on Tmall to sell selling full range of pet parasiticides.

Social innovation: catalyst for sustainable health solutions

Supporting social innovators drives sustainable health solutions in underserved communities. Learn more about Boehringer Ingelheim Social Engagements.

FDA accepts new chronic kidney disease treatment application

The Supplier Code of Conduct

BI’s expectations towards its suppliers on ethical behavior, integrity, professionalism and common business requirements.

Boehringer-Ingelheim's-half-year-figures-2021

Press release on Boehringer Ingelheim's half-year figures 2021. Business development from January to June 2021.

Why we may be more like our pets than we think

The bond between owners and their pets goes beyond physical resemblance as we are increasingly facing similar health problems.

FOYA_Shanghai

Boehringer Ingelheim’s commercial manufacturing facility in Shanghai has been awarded as “Facility of the Year”

CHMP recommends new treatment for chronic kidney disease

The CHMP of EMA has granted a positive opinion recommending empagliflozin for the treatment of adults with chronic kidney disease

Collaboration Boehringer Ingelheim Veeva technology

Boehringer Ingelheim selects Veeva Development Cloud worldwide to bring innovative therapies to patients faster

On two wheels for more animal health

Cowtribe’s social entrepreneurs win Boehringer Ingelheim's Accelerator Program.

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers